PSA density adjusts your PSA level for prostate size. A high PSA density (≥0.15 ng/mL/cc) raises concern for cancer, especially when PSA seems borderline for your gland volume.

Prostate cancer is common in men over 50. Early detection through personalized screening improves treatment outcomes, especially for those with higher risk due to age, race, family history, or genetic factors.

Focal therapy offers targeted, minimally invasive prostate cancer treatment with functional benefits, but requires careful follow-up and lacks long-term data.

Prostate cancer screening enables early detection and more treatment options but carries risks like overdiagnosis and unnecessary interventions—individualized decisions based on personal risk and values are essential.

Prostate cancer screening should be personalized based on risk factors like age, race, family history, and BRCA mutations. High-risk men may need to begin screening as early as age 40–45.

The Miami Active Surveillance Trial (MAST) highlights the safety and structure of Active Surveillance (AS), offering evidence-based guidance for monitoring low-risk prostate cancer while preserving quality of life.